Clinical Role of the Detection of Human Telomerase RNA Component Gene Amplification by Fluorescence in situ Hybridization on Liquid-Based Cervical Samples: Comparison with Human Papillomavirus-DNA Testing and Histopathology

Acta Cytologica

Volumn 59, Issue 4, 2015, Pages 345-354

  Zappacosta, Roberta ^a,b   Ianieri, Manuel Maria ^b   Buca, Danilo ^b   Repetti, Elena ^c   Ricciardulli, Alessandra ^b   Liberati, Marco ^b  

^a SS Annunziata Hospital Chieti Scalo   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Italian Diagnostic Center   (Italy)

Author keywords

3q26 chromosome; Cervical cancer prevention; Human papillomavirus; Human telomerase RNA component gene amplification

Indexed keywords

RNA; TELOMERASE; VIRUS DNA; TELOMERASE RNA;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TELOMERASE RNA COMPONENT GENE AMPLIFICATION; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR INVASION; UTERINE CERVIX CARCINOMA IN SITU; VAGINA SMEAR KIT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; FEMALE; GENE AMPLIFICATION; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA; TELOMERASE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84946471498     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000438719     Document Type: Article

References (50)

1. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
2. American Congress of Obstetricians and Gynecologists (ACOG): Practice Bulletin No. 131: screening for cervical cancer. Obstet Gynecol 2012; 120: 1222-1238.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
4. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J: Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-293.
5. Petry KU, Mention S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al: Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8,468 patients. Br J Cancer 2003; 88: 1570-1577.
6. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al: Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-3042.
7. Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al: Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006; 44: 1310-1317.
8. Matthews CP, Shera KA, McDougall JK: Genomic changes and HPV type in cervical carcinoma. Proc Soc Exp Biol Med 2000; 223: 316-321.
9. Cayuela L, Flores JM, Blasco MA: The telomerase RNA component TERC is required for the tumour-promoting effects of TERC overexpression. EMBO Rep 2005,6: 268-274.
10. Farwell DG, Shera KA, Koop JI, Bonnet GA, Matthews CP, Reuther GW, Coltreta MD, McDougall JK, Klingelhutz AJ: Genetic and epigenetic change in human epithelial cells immortalized by telomerase. Am J Pathol 2000; 156: 1537-1544.
11. Anderson S, Shera K, Ihle J, Billman L, Goff B, Greer B, Tamimi H, McDougall J, Klingelhutz A: Telomerase activation in cervical cancer. Am J Pathol 1997; 151: 25-31.
12. Hills M, Lansdorp PM: Short telomeres resulting from heritable mutations in telomerase reverse transcriptase gene predispose for a variety malignancies. Ann NY Acad Sci 2009; 1176: 178-190.
13. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
14. World Health Organization: IARC Handbooks of Cancer Prevention. Vol 10. Cervix Cancer Screening. Lyon, IARC Press, 2005, pp 1-302.
15. Obermann EC, Prince SS, Barascud A, Grilli B, Herzog M, Kaup M, Cathomas G, Frey Tirri B, et al: Prediction of outcome in patients with low-grade squamous intraepithelial lesions by fluorescence in situ hybridation analysis of human papillomavirus, TERC, and Myc. Cancer Cytopathol 2013; 8: 423-431.
16. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 1: 159-174.
17. NHSCSP Audit of Invasive Cervical Cancer: national report 2007-2010. www.cancerscreening. nhs.uk/cervical/publications/nhscsp-audit-invasive-cervicalcancer-201107.pdf (last accessed January 9, 2014).
18. Cuschieri KS, Graham C, Moore C, Cubie HA: Human papillomavirus testing for the management of low-grade cervical abnormalities in the UK. Influence of age and testing strategy. J Clin Virol 2007; 38: 14-18.
19. Arbyn M, Kyrgiou M, Simoens C: Peri-natal mortality and other severe adverse pregnancy outcome associated with treatments of cervical intraepithelial neoplasia: a meta-analysis. BMJ 2008; 337: 1284-1295.
20. Massad LS, Collins YC, Meyer PM: Biopsy correlates of abnormal cervical cytology classified using the Bethesda System. Gynecol Oncol 2001; 82: 516-522.
21. Castle PE, Gravitt PE, Wentzensen N, Schiffman M: A descriptive analysis of prevalent vs. incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am J Clin Pathol 2012; 138: 241-246.
22. Centers for Disease Control and Prevention. www.cdc.gov/std/stats/stiestimates-factsheet-feb-2013.pdf (last accessed December 28, 2014).
23. Atkins KA, Jeronimo J, Stoler MH, et al: Description of patients with squamous cell carcinoma in the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study. Cancer 2006; 108: 212-221.
24. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-355.
25. Lambert AP, Anschau F, Schmitt VM: P16 INK4a expression in cervical premalignant and malignant lesions. Exp Mol Pathol 2006,80: 192-196.
26. Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R; European CINtec Cytology Study Group: The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. Am J Clin Pathol 2010; 134: 12-21.
27. Tsoumpou I, Arbyn M, Kyrgiou M, et al: p16 INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35: 210-220.
28. Wentzenses N, Bergeron C, Cas F, Eschenbach D, Vinokurova S, von Knebel DM: Evaluation of a nuclear score for p16 INK4a -stained cervical squamous cells in liquid-based cytology samples. Cancer 2005; 105: 461-467.
29. Yang YC, Shyong WY, Chang MS, Chen YJ, Lin CH, Huang ZD, Wang Hsu MT, Chen ML: Frequent gain of copy number on long arm of chromosome 3 in human cervical adenocarcinoma. Cancer Genet Cytogenet 2001; 131: 48-53.
30. Zhang Y, Wang X, Ma L, Hu L: Clinical significance of hTERC gene amplification detection by FISH in the screening of cervical lesions. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 368-371.
31. Alemada F, Espinet B, Corzo C, Munoz R, Bellosillo B, Lloveras B, Pijuan L, Gimeno J, Salido M, Sole F, Carreras R, Serrano S: 3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases. Hum Pathol 2009; 40: 1474-1478.
32. Heselmeyer-Haddad K, Janz V, Castle PE, Chaudhri N, White N, Wilber K, Morrison LE, Auer G, Burroughs FH, Sherman ME, Ried T: Detection of genomic amplification of human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 2003; 163: 1405-1416.
33. Heitman ER, Lankachandra KM, Wall J, et al: 3q26 amplification is an effective negative triage test for LSIL: a historical prospective study. PLoS One 2012; 7: 1-7.
34. Hopman AH, Theelen W, Hommelberg PP, Kamps MA, Herrington CS, Morrison LE, Speel EJ, Smedts F, Ramaekers FC: Genomic integration of oncogenic HPV and gain of human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 2006; 210: 412-419.
35. Branca M, Giorgi C, Ciotti M, et al: Upregulation of telomerase (hTERC) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papilloma virus, virus persistence, or disease outcome in cervical cancer. Diagn Cytopathol 2006; 34: 739-748.
36. Ying L, Wen-Jie Z, Feng Y, Xin-Yu W, Wei-Guo L, Ding M, et al: Application of hTERC in ThinPrep samples with mild cytologic abnormality and HR-HPV positive. Gynecol Oncol 2011; 120: 73-83.
37. Caraway NP, Khanna A, Dawlett M, Guo M, Guo N, Lin E, Katz RL: Gain of the 3q26 region in cervicovaginal liquid-based Pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol 2008; 110: 37-42.
38. Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T: Genomic amplification of the human telomerase gene (TERC) in Pap smears predicts the development of cervical cancer. Am J Pathol 2005; 166: 1229-1238.
39. Reza Jalali G, Herzog TJ, Dziura B, Walat R, Kilpatrick MW: Amplification of the chromosome 3q26 region shows high negative predictive value for non-malignant transformation of LSIL cytologic findings. Am J Obstet Gynecol 2010; 202: 581-583.
40. Liu Z, Ma H, Wei S, Li G, Sturgis EM: Telomere length and TERT functional polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 2011; 20: 2642-2648.
41. de Cremoux P, Coste J, Sastre-Garau X, et al: Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening: a study by the French Society of Clinical Cytology. Am J Clin Pathol 2003; 120: 492-499.
42. Adams AL, Eltoum I, Roberson J, et al: Negative colposcopic biopsy after positive human papilloma virus (HPV) DNA. Am J Clin Pathol 2006; 125: 413-418.
43. Molano M, van den Brule A, Plummer M, et al: Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158: 486-494.
44. Jin G, Yoo SS, Cho S, Jeon HS, Lee WK: Dual roles of a variable number of tandem repeat polymorphisms in the TERT gene in lung cancer. Cancer Sci 2011; 102: 144-149.
45. Hsu CP, Lee LW, Shai SE, Chen CY: Clinical significance of telomerase and its associate genes expression in the maintenance of telomere length in squamous cell carcinoma of the esophagus. World J Gastroenterol 2005; 11: 6941-6947.
46. Safont MJ, Gil M, Sirera R, Jantus-Lewintre E, Sanmartin E: The prognostic value of hTERT expression levels in advanced-stage colorectal cancer patients: a comparison between tissue and serum expression. Clin Transl Oncol 2011; 13: 396-400.
47. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S: hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60: 809-818.
48. Zhang B, Beeghly-Fadiel A, Long J, Zheng W: Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011; 12: 477-488.
49. Andersson S, Wallin KL, Hellstrom AC, Morrison LE, Hjerpe A: Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. Br J Cancer 2006; 95: 331-338.
50. Aulmann S, Schleibaum J, Penzel R, Schirmacher P, Gebauer G: Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. J Clin Pathol 2008; 61: 1034-1037.